The SA Journal Diabetes & Vascular Disease Volume 18 No 2 (November 2021)

for SUSTAINED CONTROL For further product information contact PHARMA DYNAMICS P O Box 30958 Tokai Cape Town 7966 Fax +27 21 701 5898 Email info@pharmadynamics.co.za CUSTOMER CARE LINE 0860 PHARMA (742 762) / +27 21 707 7000 www.pharmadynamics.co.za DYNA GLICLAZIDE SR 30 mg . Each tablet contains 30 mg gliclazide. S3 A42/21.2/0249. NAM NS2 12/21.2/0110. For full prescribing information, refer to the professional information approved by SAHPRA, 28 July 2017. 1) Crepaldi G and Fioretto P. Gliclazide modified release: Its place in the therapeutic armamentarium. Metabolism 2000;49(10)supplement 2:21-25. 2) McGavin JK, et al . Gliclazide modified release. Drugs 2002;62(9):1357-1364. * Conditions apply. DGLL732/05/2021. Once daily formulation Improved compliance 1 Sustained 24 hour glycaemic control 2 60 ’ s Packed in Within reference at major medical schemes. *